Muscle Atrophy - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Muscle Atrophy - Pipeline Review, H2 2018’, provides an overview of the Muscle Atrophy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Muscle Atrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Muscle Atrophy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Muscle Atrophy

- The report reviews pipeline therapeutics for Muscle Atrophy by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Muscle Atrophy therapeutics and enlists all their major and minor projects

- The report assesses Muscle Atrophy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Muscle Atrophy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Muscle Atrophy

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Muscle Atrophy pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Fate Therapeutics Inc

Igenomix SL

K-Stemcell Co Ltd

Milo Biotechnology LLC

Shionogi & Co Ltd

Spherium Biomed SL

Teijin Pharma Ltd

Fate Therapeutics Inc

Igenomix SL

K-Stemcell Co Ltd

Milo Biotechnology LLC

Shionogi & Co Ltd

Spherium Biomed SL

Teijin Pharma Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscle Atrophy - Overview

Muscle Atrophy - Therapeutics Development

Pipeline ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Muscle Atrophy - Overview

Muscle Atrophy - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Muscle Atrophy - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Muscle Atrophy - Companies Involved in Therapeutics Development

Fate Therapeutics Inc

Igenomix SL

K-Stemcell Co Ltd

Milo Biotechnology LLC

Shionogi & Co Ltd

Spherium Biomed SL

Teijin Pharma Ltd

Muscle Atrophy - Drug Profiles

AAV9-Follistatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EMMY-105 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EMMY-106 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FT-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JP-4039 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit HSD11B1 for Muscle Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SP-15028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Parry-Romberg disease and Thromboangiitis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TEISARM-2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Muscle Atrophy - Dormant Projects

Muscle Atrophy - Discontinued Products

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Muscle Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Tables

Number of Products under Development for Muscle Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Muscle Atrophy - Pipeline by Fate Therapeutics Inc, H2 2018

Muscle Atrophy - Pipeline by Igenomix SL, H2 2018

Muscle Atrophy - Pipeline by K-Stemcell Co Ltd, H2 2018

Muscle Atrophy - Pipeline by Milo Biotechnology LLC, H2 2018

Muscle Atrophy - Pipeline by Shionogi & Co Ltd, H2 2018

Muscle Atrophy - Pipeline by Spherium Biomed SL, H2 2018

Muscle Atrophy - Pipeline by Teijin Pharma Ltd, H2 2018

Muscle Atrophy - Dormant Projects, H2 2018

Muscle Atrophy - Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Muscle Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products ...

List of Figures

Number of Products under Development for Muscle Atrophy, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Targets, H2 2018

Number of Products by Stage and Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports